Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

Am J Hematol. 2010 May;85(5):386-9. doi: 10.1002/ajh.21689.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benzamides
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Practice Guidelines as Topic
  • Prospective Studies
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction
  • Splenomegaly / complications*
  • Treatment Failure

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate